Inactivation of Sox9 in fibroblasts reduces cardiac fibrosis and inflammation
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsScharf, Gesine M.
Conway, Simon J.
Wollert, Kai C.
MetadataShow full item record
AbstractFibrotic scarring drives the progression of heart failure after myocardial infarction (MI). Therefore, the development of specific treatment regimens to counteract fibrosis is of high clinical relevance. The transcription factor SOX9 functions as an important regulator during embryogenesis, but recent data point towards an additional causal role in organ fibrosis. We show here that SOX9 is upregulated in the scar after MI in mice. Fibroblast specific deletion of Sox9 ameliorated MI-induced left ventricular dysfunction, dilatation and myocardial scarring in vivo. Unexpectedly, deletion of Sox9 also potently eliminated persisting leukocyte infiltration of the scar in the chronic phase after MI. RNA-sequencing from the infarct scar revealed that Sox9 deletion in fibroblasts resulted in strongly downregulated expression of genes related to extracellular matrix, proteolysis and inflammation. Importantly, Sox9 deletion in isolated cardiac fibroblasts in vitro similarly affected gene expression as in the cardiac scar and reduced fibroblast proliferation, migration and contraction capacity. Together, our data demonstrate that fibroblast SOX9 functions as a master regulator of cardiac fibrosis and inflammation and might constitute a novel therapeutic target during MI.
CitationJCI Insight. 2019 Jul 16;5. pii: 126721. doi: 10.1172/jci.insight.126721.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Amphiregulin enhances cardiac fibrosis and aggravates cardiac dysfunction in mice with experimental myocardial infarction partly through activating EGFR-dependent pathway.
- Authors: Liu L, Jin X, Hu CF, Zhang YP, Zhou Z, Li R, Shen CX
- Issue date: 2018 Jan 18
- Cardiac Fibroblast-Specific Activating Transcription Factor 3 Promotes Myocardial Repair after Myocardial Infarction.
- Authors: Li YL, Hao WJ, Chen BY, Chen J, Li GQ
- Issue date: 2018 Oct 5
- Haplodeficiency of activin receptor-like kinase 4 alleviates myocardial infarction-induced cardiac fibrosis and preserves cardiac function.
- Authors: Chen YH, Wang Q, Li CY, Hou JW, Chen XM, Zhou Q, Chen J, Wang YP, Li YG
- Issue date: 2017 Apr
- Tomo-Seq Identifies SOX9 as a Key Regulator of Cardiac Fibrosis During Ischemic Injury.
- Authors: Lacraz GPA, Junker JP, Gladka MM, Molenaar B, Scholman KT, Vigil-Garcia M, Versteeg D, de Ruiter H, Vermunt MW, Creyghton MP, Huibers MMH, de Jonge N, van Oudenaarden A, van Rooij E
- Issue date: 2017 Oct 10
- Reduced scar maturation and contractility lead to exaggerated left ventricular dilation after myocardial infarction in mice lacking AMPKα1.
- Authors: Noppe G, Dufeys C, Buchlin P, Marquet N, Castanares-Zapatero D, Balteau M, Hermida N, Bouzin C, Esfahani H, Viollet B, Bertrand L, Balligand JL, Vanoverschelde JL, Beauloye C, Horman S
- Issue date: 2014 Sep